Clinical Outcomes of SAMe and Nicotinamide Riboside Supplementation in a Child with Arts Syndrome: Case Report

Objectives

To examine the effects of supplementation of S-adenosylmethionine (SAMe) and NR in a child with Arts syndrome and compare to previous Arts syndrome patients who received SAMe with or without NR.

Journal

JIMD Reports

Key Outcomes

• By 21 months, the patient demonstrated notable developmental progress, including walking without a walker, and recovered from early upper respiratory infections without loss of skills, muscle tone, or increased respiratory needs.
• At 24 months, the patient experienced respiratory failure and cardiac arrest secondary to rhinovirus/enterovirus, resulting in temporary loss of independent sitting and oral feeding by the end of the visit.
• Within two months post-discharge, he regained independent sitting, crawling, speech, and oral feeding, and later tolerated another upper respiratory infection without clinical decline.
• Overall, the patient showed sustained improvements in strength, endurance, and developmental milestones over time, consistent with clinical benefits observed in other Arts syndrome patients treated with SAMe alone or SAMe plus NR.

Duration

SAMe: 200 mg/day at 19 months, followed by 400 mg/day at 20 months

NR: 300 mg/day beginning at 20 months until 28 months

Dose

SAMe: 200, followed by 400 mg

NR: 300 mg

Study Design

Retrospective, single-patient, clinical case study of a 28-month-old male child with Arts syndrome